List of investigational sexual dysfunction drugs explained
This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical treatment of sexual dysfunction but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in June 2017. It is likely to become outdated with time.
Atrophic vaginitis
Erectile dysfunction
Female anorgasmia
Female sexual dysfunction
- BP-101 – undefined mechanism of action (BP 101 - Ovoca Bio - AdisInsight)
- Bupropion/trazodone (S1P-104, S1P-205, Lorexys, Orexa) – norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor antagonist, 5-HT2A receptor antagonist, α1-adrenergic receptor antagonist, weak serotonin reuptake inhibitor (Bupropion/trazodone - AdisInsight)
- Buspirone/testosterone (Lybridos) – 5-HT1A receptor partial agonist and androgen receptor agonist (Buspirone/testosterone - Emotional Brain - AdisInsight)
- Lasofoxifene (CP-336156, CP-336156-CB, Fablyn, Oporia) – selective estrogen receptor modulator (Lasofoxifene - Sermonix Pharmaceuticals - AdisInsight)
- PL-6983 – selective MC4 receptor agonist (Research programme: sexual dysfunction therapy - Palatin Technologies - AdisInsight)
- Sildenafil/testosterone (Lybrido) – PDE5 inhibitor and androgen receptor agonist (Sildenafil/testosterone - Emotional Brain - AdisInsight)
- TGFK09SD – 5-HT1A receptor agonist (TGFK 09SD - AdisInsight)
Premature ejaculation
Unspecified
See also
- List of investigational drugs
External links